Literature DB >> 26482307

Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.

Hervé Dupont1, Olivier Gaillot2, Anne-Sophie Goetgheluck3, Claire Plassart4, Jean-Philippe Emond5, Marion Lecuru6, Nicolas Gaillard6, Sarah Derdouri6, Baptiste Lemaire6, Marion Girard de Courtilles6, Vincent Cattoir7, Hedi Mammeri8.   

Abstract

An interregional surveillance program was conducted in the northwestern part of France to determine the prevalence of carbapenem-nonsusceptible Enterobacteriaceae (CNSE) isolates and their susceptibility to ceftazidime-avibactam and aztreonam-avibactam combinations. Nonduplicate CNSE clinical isolates were prospectively collected from six hospitals between June 2012 and November 2013. MICs of ceftazidime and aztreonam, alone or combined with a fixed concentration of avibactam (4 μg/ml), and those of carbapenems (comparator agents) were determined. MICs of ertapenem in combination with phenylalanine arginine-naphthylamide dihydrochloride (PAβN) were also determined to assess active efflux. Genes encoding carbapenemases, plasmid-mediated AmpC enzymes, extended-spectrum β-lactamases (ESBLs), and major outer membrane proteins (OMPs) were amplified and sequenced. OMPs were also extracted for SDS-PAGE analysis. Among the 139 CNSE isolates, mainly Enterobacter spp. and Klebsiella pneumoniae, 123 (88.4%) were ertapenem nonsusceptible, 12 (8.6%) exhibited reduced susceptibility to all carbapenems, and 4 Proteeae isolates (2.9%) were resistant to imipenem. Carbapenemase production was detected in only two isolates (producing OXA-48 and IMI-3). In contrast, OMP deficiency, in association with AmpCs and/or ESBLs (mainly CTX-M-9, SHV-12, and CTX-M-15), was largely identified among CNSE isolates. The ceftazidime-avibactam and aztreonam-avibactam combinations exhibited potent activity against CNSE isolates (MIC50/MIC90, 1/1 μg/ml and 0.5/0.5 μg/ml, respectively) compared to that of ceftazidime and aztreonam alone (MIC50/MIC90, 512/512 μg/ml and 128/512 μg/ml, respectively). This study reveals the in vitro activity of ceftazidime-avibactam and aztreonam-avibactam combinations against a large collection of porin-deficient enterobacterial isolates that are representative of the CNSE recovered in the northern part of France.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26482307      PMCID: PMC4704208          DOI: 10.1128/AAC.01559-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Omp35, a new Enterobacter aerogenes porin involved in selective susceptibility to cephalosporins.

Authors:  Charléric Bornet; Nathalie Saint; Lilia Fetnaci; Myrielle Dupont; Anne Davin-Régli; Claude Bollet; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae.

Authors:  George A Jacoby; Debra M Mills; Nancy Chow
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  In vivo acquisition of high-level resistance to imipenem in Escherichia coli.

Authors:  Laurent Poirel; Claire Héritier; Colette Spicq; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

5.  Carbapenem-nonsusceptible strains of Klebsiella pneumoniae producing SHV-5 and/or DHA-1 beta-lactamases in a Czech hospital.

Authors:  Eva Chudácková; Tamara Bergerová; Karel Fajfrlík; Dana Cervená; Pavla Urbásková; Joanna Empel; Marek Gniadkowski; Jaroslav Hrabák
Journal:  FEMS Microbiol Lett       Date:  2010-05-17       Impact factor: 2.742

6.  Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species.

Authors:  G M Carlone; M L Thomas; H S Rumschlag; F O Sottnek
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

7.  Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital.

Authors:  R J Drew; J F Turton; R L R Hill; D M Livermore; N Woodford; S Paulus; N A Cunliffe
Journal:  J Hosp Infect       Date:  2013-07-05       Impact factor: 3.926

8.  In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors:  Henry Li; Mark Estabrook; George A Jacoby; Wright W Nichols; Raymond T Testa; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

9.  An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.

Authors:  Aurora García-Fernández; Vivi Miriagou; Costas C Papagiannitsis; Alessandra Giordano; Mario Venditti; Carlo Mancini; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

10.  Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.

Authors:  Michel Doumith; Matthew J Ellington; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2009-02-20       Impact factor: 5.790

View more
  25 in total

1.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate.

Authors:  Hervé Dupont; Pascaline Choinier; David Roche; Sandine Adiba; Megan Sookdeb; Catherine Branger; Erick Denamur; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Within-a-Day Detection and Rapid Characterization of Carbapenemase by Use of a New Carbapenem Inactivation Method-Based Test, CIMplus.

Authors:  François Caméléna; Aurélie Cointe; Vincent Mathy; Claire Hobson; Catherine Doit; Béatrice Bercot; Dominique Decré; Isabelle Podglajen; Laurent Dortet; Audrey Monjault; Philippe Bidet; Stéphane Bonacorsi; André Birgy
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

4.  In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

Authors:  Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif.

Authors:  Clément Ourghanlian; Daria Soroka; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Combination of Amino Acid Substitutions Leading to CTX-M-15-Mediated Resistance to the Ceftazidime-Avibactam Combination.

Authors:  Fabrice Compain; Delphine Dorchène; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 8.  Porins and small-molecule translocation across the outer membrane of Gram-negative bacteria.

Authors:  Julia Vergalli; Igor V Bodrenko; Muriel Masi; Lucile Moynié; Silvia Acosta-Gutiérrez; James H Naismith; Anne Davin-Regli; Matteo Ceccarelli; Bert van den Berg; Mathias Winterhalter; Jean-Marie Pagès
Journal:  Nat Rev Microbiol       Date:  2019-12-02       Impact factor: 60.633

Review 9.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.